Gene therapy is a novel therapy for melanoma. To date, however, there is still no powerful tumor specific promoter (TSP) to restrict the transgene expression in melanoma cells. In order to define a useful TSP for targeting in the context of melanoma gene therapy, four promoters, the cyclooxygenase-2 (Cox-2), a-chemokine SDF-1 receptor (CXCR4), epithelial glycoprotein 2 (EGP-2), and survivin, were tested in both established melanoma cell lines and primary melanoma cells. We employed recombinant adenoviral vectors (reAds) each with a candidate TSP (the Cox-2, CXCR4, EGP-2, or survivin), a reporter luciferase gene, and a poly-A signal, all of which were inserted into the E1-deleted region. A reAdGL3Bcytomegalovirus (CMV), containing the CMV promoter and luciferase gene, was used as a positive control to normalize the luciferase activity. Luciferase activity was measured in multiple tumor cell lines and two primary melanoma cell cultures after infection with reAds. Human epithelial melanocytes, HEM, were used as normal control. In contrast to three other promoters, the survivin promoter exhibited the highest activities within both melanoma cell lines and primary melanoma cells, but not in HEMs. Additionally, the survivin promoter exhibited very low activities in major mouse organs including the liver, in vivo. EGP-2 is not active in melanoma; messenger RNA expressions were correlated to promoter activities both in melanoma cell lines and primary cell cultures. Thus, these data suggest that the survivin promoter achieved a 'tumor-on/ liver-off' profile, and thus represents a potentially useful tumor-specific promoter with applications for transcriptional targeting of Ad vector-based cancer gene therapy or oncolysis to melanoma. Gene Therapy (2005) 12, 330-338.
Introduction
Melanoma is the most deadly form of skin cancer and is currently the eighth most common cancer in the United States. 1 In Caucasians, the incidence of melanoma continues to rise at a rate of approximately 5% per year. 2 The corresponding figures are 32 100 new cases and 7200 deaths each year in the United States. Malignant melanoma frequently metastasizes to regional lymph nodes and to distant sites at early stages of tumor progression and is refractory to current therapies once spread. There are four major modalities of treatment of disease in melanoma: (1) surgery, (2) chemotherapy, (3) immunotherapy, and (4) radiation. Although the overall prognosis is excellent for primary cutaneous melanoma diagnosed early and treated by adequate therapies, 5-year survival for patients is only 54% and prognosis of disseminated melanoma is poorer, with 5-year survival of about 6%. 3 With the high degree of malignancy and poor outcomes, this disease has strongly stimulated studies and clinical trials to define promising new therapies.
Gene therapy and virotherapy might be novel therapies for melanoma. The former transfers a therapeutic gene for mutation compensation, immunopotentiation, or prodrug activation. 4 The latter results in tumor cell killing by oncolysis, virus replication-induced cell lysis. 5 Both of these therapeutic interventions allow for specific antitumor effects via molecular targeting strategies that exploit tumor markers. To date, gene therapy approaches have not realized a significant therapeutic end point in human clinical trails. Poor tumor transduction efficiency and nonspecific transcription are key factors limiting realization of the potential of cancer gene therapy. 6, 7 Various approaches have been developed to enhance the infectivity of current vector systems in order to address poor tumor cell transduction efficiency. In parallel, both transductional and transcriptional targeting strategies have been employed. [8] [9] [10] [11] [12] [13] These enhance the transduction selectivity of current vector systems for tumor cells in order to address the concerns with regard to normal tissue transfection and toxicity. With transductional targeting, vector systems are modified in a manner to achieve tumor cell binding/entry specifically. With transcriptional targeting, gene expression of interest is under control of a promoter that maintains a 'tumor-on' status, and a 'normal tissue-off' or 'liver-off' status. Numerous tissue-or tumor-specific promoters (TSP) have been explored in adenovirus. To develop the transcriptional targeting of gene therapy for melanoma, the need has been established to define promoters, which have potential utility. In this regard, the following four TSPs, the epithelial glycoprotein 2 (EGP-2), cyclooxygenase-2 (Cox-2), a-chemokine SDF-1 receptor (CXCR4) and survivin promoter, were chosen in this study because the corresponding genes are overexpressed in a variety of cancers, but minimally expressed in normal host tissues. Recently, we showed expression of Cox-2 transcripts in all tested human melanoma cell lines, including a mouse melanoma cell line. This expression was not present in HEMs, which thereby established tumor specificity of the Cox-2 promoter in melanoma. Potentially, the Cox-2 promoter will have applications for transcriptional targeting of Ad vector-based cancer gene therapy to melanoma.
14 Mü ller et al 15 have demonstrated that CXCR4 expression is markedly upregulated in breast cancer and in a variety of cancer cells including melanoma, but undetectable in normal mammary epithelial cells. Survivin is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and the progression of malignancies. 16 Survivin expression is found during embryonic and fetal development 17 and in different tumors, [18] [19] [20] but is undetectable in terminally differentiated adult tissue. 21 Andersen et al 22 described that since survivin is expressed by a variety of different tumors, MHC-restricted survivin epitopes may serve as important and widely applicable targets for anticancer immunotherapeutic strategies. Finally, EGP-2 is a 40 kDa cell adhesion molecule also know as Ep-CAM or the pancarcinoma-associated antigen 17-1A and is encoded by the GA-733-2 gene. 23, 24 This antigen is highly expressed on a variety of adenocarcinomas of different origin such as the breast, ovarian, colon, and lung; [25] [26] [27] however, EGP-2 expression has not been described in melanoma.
In this study, we compared the promoter activities of four TSPs in recombinant adenoviruses (reAds), all of which had a profile of 'liver-off' in in vivo experiments. The data demonstrated that three promoters, including the Cox-2, CXCR4, and survivin, have high activities in established melanoma cell lines but not the EGP-2 promoter. The survivin promoter appears to be a superior TSP for melanoma targeting among them because it had high activity in established cell lines with lower variation and low activity in HEMs. The survivin promoter also showed high activities in primary melanoma cells compared to the EGP-2 promoter. Thus, the survivin promoter is a promising candidate for applications of transcriptional targeting of Ad vector-based cancer gene therapy or oncolysis for melanoma.
Materials and methods

Cell lines and animals
Human melanoma cell lines SK-MEL-28 (American Type Culture Collection (ATCC), Manassas, VA, USA), A375M (kindly provided by Dr IJ Fidler, Houston, TX, USA), Mel-624 (kindly provided by Dr J Schlom, Bethesda, MD, USA), and MeWo (kindly provided by Dr I Hart, London, UK) were cultured according to the ATCC manual instructions (Manassas, VA, USA). Briefly, SK-MEL-28 and MeWo cells were cultured in DMEM (Dulbecco's modified Eagle's medium), 10% FBS (fetal bovine serum), 4.5 mg/L-glucose, 100 IU/ml penicillin and 100 mg/ml streptomycin, and 2 mM L-glutamine. A375M and Mel-624 cells were cultured in RPMI 1640, with 10% FBS, 2 mM L-glutamine, and 100 IU/ml and 100 mg/ml of penicillin and streptomycin, respectively. Control cells, HEMs (Cell Application Inc., San Diego, CA, USA), were cultured in melanocyte growth medium purchased from Cell Application Inc. (San Diego, CA, USA). Two primary melanoma cells, P-1 and P-2, were kindly provided by Dr Detlef Dieckmann (Erlangen, Germany) and were cultivated in RPMI containing 10% FCS, 20 mg/ml gentamycin (Sigma, Deisenhofen, Germany), and 2 mM L-glutamine. Cells were grown at 371C in a humidified atmosphere containing 5% CO 2 .
Gene expression detected by real-time quantitative PCR
Total cellular RNA was extracted from 5 Â 10 5 cells using the RNeasy Mini kit (Qiagen, Valencia, CA, USA), followed by treatment with RNase-free DNase to remove any possible contaminating DNA from the RNA samples. The fluorescent TaqMan probes and the primer pairs used for real-time PCR in analysis of four gene messenger RNAs (mRNAs), including Cox-2, CXCR4, EGP-2, and survivin genes, were designed using Primer Express 1.0 (Perkin-Elmer, Foster City, CA, USA), listed in Table 1 , and synthesized by Applied Biosystems (Foster City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. For real-time PCR assay, each 9 ml PCR reaction contained 3 mM MgCl 2 , 300 mM each dATP, dCTP, and dGTP, 600 mM dUTP, 100 nM of forward, reverse primers, and probe, 1 U of rTth DNA polymerase, 0.025% BSA, and RNase-free water. Plasmid standard or 1 ml of RNA sample was added into each assay tube. Negative controls with no template were performed for each reaction series. Real-time PCR reaction was carried out using a LightCyclert System (Roche Molecular Biochemicals, Indianapolis, IN, USA). Thermal cycling conditions were subjected to 2 min at 501C, 30 min at 601C, 5 min at 951C, then 40 cycles of 20 s at 941C, and 1 min at 621C. Data were analyzed with LightCycler software.
Expression vectors and reAds
Five reAds were used in this study, including reAdGL3Bcytomegalovirus (CMV) reAdGL3BCox-2, reAdGL3BCXCR4, reAdGL3BEGP-2, and reAdGL3BSur-vivin. All reAds were constructed through homologous recombination in Escherichia coli using the AdEasy system. 28, 29 Transgene cassettes were located in the E1-deleted region of the E3-deleted Ad backbones. Two reAds, AdGL3BCMV and AdGL3BCox-2, are E1 and E3 deleted and have a transgene cassette in E1-deleted region containing CMV/Cox-2 promoter, respectively, the luciferase gene, and simian virus 40 polyadenylation signal, in which the later two parts were derived from pGL3Basic (Promega, Madison, WI, USA). The luciferase Promoter activity in melanoma B Lu et al is induced by enhancer/CMV or the 924 base pairs (bp) Cox-2 promoter, respectively.
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The other reAds, reAdGL3BCXCR4, reAdGL3BEGP-2, and reAdGL3BSur-vivin, have similar structure but different promoters. 30, 31 Thus, all five reAds had the same Ad backbone containing a luciferase reporter gene sequence driven by different promoters in different reAds. The viruses were propagated in the adenovirus-packaging cell line, 293, and purified by double CsCl density-gradient ultracentrifugation, followed by dialysis against phosphatebuffered saline with 10% glycerol. Physical particle concentration of virus (viral particles (vp)/ml) was determined by OD 260 reading, and biological activity (plaque-forming units, PFU/ml) was determined by standard plaque assay on 293 cells.
Analysis of the promoter activity of reAds in vivo
To analyze the promoter transcriptional activity of reAds in mouse organs, C57BL/6 mice were injected with a dose of 5 Â 10 8 PFU via the tail vein. After 2 days, major organs, including the liver, lungs, kidneys, spleen, intestines, heart, and muscles, were harvested to measure luciferase expression. All the organs were frozen on dry ice, ground to a fine powder with a mortar and pestle in an ethanol/dry ice bath. The tissue powder was lysed with Cell Culture Lysis Buffer (Promega, Madison, MI, USA) and after three rounds of freezing and thawing, samples were centrifuged to obtain supernatant. The recovered supernatants were analyzed for luciferase activity with the Luciferase Assay System (Promega) on a Luminocount (Wallac Inc., Gaithersburg, MA, USA). Protein determination was performed by using Bio-Rad Protein Assay Kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). The luciferase activities were normalized to protein levels. The relative activities of promoters in reAds were evaluated by the percentage of RLU (relative light units) ¼ RLU driven by a TSP/RLU driven by CMV promoter Â 100%.
Analysis of the promoter activity of reAds in vitro
For determination of transcriptional activity of reAds, 5 Â 10 4 cells of each established cancer cell line and normal control HEM were plated in 24-well tissue plates and infected with one of the reAds described above at an MOI of 10 PFU/cell in 200 ml of individual growth medium containing 2% FBS (infection medium). The infection medium was replaced by the fresh medium containing 10% FBS after 3 h. After 48 h postinfection, luciferase activity was determined using the Reporter Lysis Buffer and Luciferase Assay System of Promega (Madison, WI, USA) following the manufacturer's protocol. Experiments were performed in triplicate and luciferase activities were standardized with RLU of the CMV promoter (the CMV promoter activity is 100%).
Comparison of the transcriptional activity of the survivin promoter with that of the EGP-2 promoter in primary melanoma cells
The primary melanomas, P-1 and P-2, were plated in 24-well plates at 5 Â 10 4 cells/well. The following day, cells were infected with reAdGL3BSurvivin or reAd-GL3BEGP-2 at an MOI of 10 PFU/cell in 200 ml of RPMI 1640 containing 2% FBS (infection medium). The infection medium was replaced by the fresh medium after 3 h. At 48 h after infection, luciferase activity was determined in the primary melanoma cells. In both the primary melanoma cells and a normal cell line, HEM, mRNA levels of the survivin gene were determined by real-time PCR described above.
Statistical analysis
The luciferase activities measured in this study were analyzed by t-test using Statistics Analysis Software 8. 
Results
In vivo analysis of four promoter activities in mouse organs after Ad gene transfer
Four viruses, reAdGL3BCox-2, reAdGL3BCXCR4, reAdGL3BEGP-2, and reAdGL3BSurvivin, as well as reAdGL3BCMV (positive control), were used in this study. The luciferase expression levels reflect the transcriptional activities of each promoter. AdGL3B CMV is a positive control, in which the luciferase reporter gene is driven by the strong CMV promoter, to normalize the activities of the other promoters. The reAds (5 Â 10 8 PFU) were administered intravenously to mice (C57BL/6) to measure the activities of the TSPs compared to the CMV promoter in major organs, including the liver, heart, spleen, lung, intestine, kidney, and muscles. These results are shown in Table 2 . All of the promoter activities in the liver were low compared to that induced by the CMV promoter; they were 0.32, 0.07, 0.0024, and 0.067% in the CXCR4, survivin, Cox-2, and EGP-2 promoter, respectively, which demonstrated all of these four promoters showed a 'liver-off' profile. The CXCR4 promoter had a high expression in the kidney, which showed 44% of luciferase level of the CMV promoter and the other two promoters, the Cox-2 and EGP-2, had high activities in the intestine compared to the CMV promoter (120 and 110%), respectively; they seemed tissue specific for the kidney and intestine, and might be good candidates to upregulate transgene in corresponding tissues. Of the four promoters, the survivin promoter exhibited the lowest background activity in all of the tested organs, including the liver (0.07% of the CMV activity). Although luciferase activity was 28.1% of the CMV promoter in the intestine, the absolute value in the intestine (776 RLU/mg protein) was only less than 4% of that in the liver (29 826 RLU/mg protein).
Gene expression quantification in melanoma cell lines by real-time PCR
To address the relevance of the candidate TSPs for malignant melanoma and a potential means for targeting of therapeutic genes to this tumor, we analyzed the Cox-2, CXCR4, EGP-2, and survivin gene expression by realtime PCR for mRNA transcripts in a set of four human melanoma cell lines, Mel-624, A375M, SK-MEL-28, and MeWo, and a control HEM cell line, HEM. Real-time PCR and applied primers and probes were described in the Materials and methods and are listed in Table 1 . mRNA copy numbers, which were derived from cDNA by RT PCR from gene expression, are shown in Figure 1 . Three gene mRNAs, including that of Cox-2, CXCR4, and survivin genes, were detected at high levels in all tested malignant melanoma cell lines. EGP-2 had low levels in all of melanoma cell lines. In addition, the survivin mRNA level is also low compared to that of the Cox-2 and CXCR4 gene in the control cell line, HEM. These results suggested that the survivin promoter represented a good candidate for transcriptional targeting of melanoma because of its high expression in melanomas and low expression in HEM ( Figure 1 ) and major organs ( Table 2) .
Analysis of candidate promoters for transcriptional targeting of adenovirus-mediated gene expression to melanoma cell lines
As seen in Figure 1 and Table 2 , expression of each gene corresponds to endogenous promoter activity in melanoma cell lines and in vivo experiments. To exploit these activities for gene therapy applications, we analyzed four replication-deficient adenoviruses (reAdGL3B/Cox-2, reAdGL3B/CXCR4, reAdGL3B/EGP-2, and reAdGL3B/ Survivin) containing different promoters, each driving luciferase. The activity of the promoter in reAds is reflected by the luciferase expression level. To analyze the activities of the promoters in adenovirus-mediated gene expression context, cell lines were infected with these reAds and reAdGL3CMV. The CMV promoter in reAdGL3BCMV has strong activity in all of the four melanoma cell lines, and serves as a positive control. All of the luciferase expression levels (RLU), which were induced by different promoters, were normalized by the expression levels induced by the CMV promoter in Figure 1 (panels b and c) . The variations from each individual experiment (triplicate) were less than 5%. As shown in Figure 2 (panel a) , the luciferase levels were elevated in three promoters, the Cox-2, CXCR4, and survivin, but not the EGP-2 promoter in four melanoma cell lines (SK-MEL-28, A375M, MeWo, and Mel-624), when compared to CMV, the positive control promoter. The activities of luciferase driven by the Cox-2, CXCR4, and survivin were one to two logs lower than that of the CMV promoter and the activity of luciferase driven by the EGP-2 promoter was three to four logs lower in four different melanoma cell lines. In Figure 2 (panel b) , the data showed the luciferase activities in the percentage of RLU of the CMV promoter for different promoters in four different melanoma cell lines. Three gene promoters, including the Cox-2, CXCR4, and survivin, have high percentages compared to the CMV promoter, but not the EGP-2. Further, the CXCR4 promoter might not be a good candidate of TSP to melanoma because of high Promoter activity in melanoma B Lu et al background (7.7%) in HEM. This number is higher than the average luciferase activities in four melanoma cell lines (range from 3.0 to 12% with an average 6.8%). Figure 2c shows the averages of luciferase activities in four melanoma cell lines were 4.5, 6.9, 0.01, and 5.9% relative to the CMV promoter for the Cox-2, CXCR4, EGP-2, and survivin, respectively. The EGP-2 promoter, which had very low activity in melanoma cell lines, was not specific to melanomas. The other promoters had similar activities in melanoma cell lines. However, the Cox-2 promoter had a mean of 4.5% of luciferase activity of the CMV promoter with a significant variation (14, 0.4 2.1, and 0.85%) of luciferase activity induced by the CMV promoter in SK-MEL-28, A375M, MeWo, and Mel-624 cell lines, respectively. Compared to the Cox-2 promoter, the survivin showed higher promoter activity (5.9%) with a narrow variation (7.2, 3.4, 9.1, and 4%) for SK-MEL-28, A375M, MeWo, and Mel-624 cell lines, respectively. Also the survivin promoter had a low background of 0.8% in HEM (Figure 2b ). Compared to both of the EGP-2 promoter and HEM control, the survivin promoter showed significant difference with a P-value o0.01. From all of these data, we concluded that the survivin promoter is an excellent candidate of TSP to melanoma with a 'tumor-on/liver-off' profile.
Analysis of the survivin and EGP-2 promoter for transcriptional targeting of adenovirus-mediated gene expression to primary melanoma cells and the control, HEM
To further analyze the TSP in a system that closely recapitulates the clinical situation, primary melanoma cells from two patients, P-1 and P-2, were measured by real-time PCR for endogenous gene expression and infected with reAds at an MOI of 10 PFU/cell for transcriptional targeting as described previously. mRNA levels of the two genes, EGP-2, 32 and survivin, are shown in Figure 3a . The EGP-2 gene was expressed very low in both two primary melanoma cells and HEM, less than 2.5 copies/ng total RNA. The survivin gene, however, was expressed at elevated levels in both primary melanoma cells (22.5 and 17.6 copies/ng total RNA in P-1 and P-2, respectively), which was seven-to 10-fold higher than that in HEM. Figure 3b shows the evaluation of the EGP-2 and survivin promoter in primary melanoma cells and the control, HEM. Both the EGP-2 and survivin promoter were expressed at low percentage (less than 0.1%) compared to the CMV promoter in control cell line, HEM. The survivin promoter had high activity in both primary melanoma cells, P-1 and P-2, which showed 5.1 and 11.3% of CMV activity, respectively, but not the EGP-2 promoter, which showed less than 0.1% of the CMV promoter activity. The mRNA levels of the two analyzed genes correlated with transcriptional activities of their corresponding promoters in reAd contexts in two melanoma primary samples.
Discussion
Ad vectors are widely used as gene transfer vectors in cancer therapy because of their ability to infect a wide range of host tissues and because of their ability to infect both proliferating and nonproliferating cells. However, they show a lack of specificity. This may lead to infection of normal host tissues with an unfortunate accompanying potential for toxicity. 33, 34 To enhance the therapeutic index, investigators have attempted to approach both transductional targeting and transcriptional targeting of Ad gene transfer. Transductional targeting approaches alter the tropism of viral vectors to achieve the required levels of efficiency and give specificity to the tumor cells. Transcriptional targeting methods utilizing TSPs to restrict transgene expression to tumor cells have been promising. 12, 35 Various promoters have been evaluated for transcriptional targeting. [36] [37] [38] However, the weakness of currently available TSPs, despite their name, is their lack of sufficient tumor specificity to avoid expression in normal tissues. Thus, a continued search for a true TSP, by which the transgene expression is induced at higher levels in tumor cells and at lower levels in normal host cells, including melanocytes, is warranted.
In this study, we presented four promoters, the Cox-2, CXCR4, EGP-2, and survivin promoter, which were candidates for specificity in melanoma, and compared them in melanoma cell lines, primary melanoma cells, and HEMs as a normal control. Cox-2 is an inducible isoform of the cyclooxgenase family and is virtually undetectable in most tissues under physiological conditions. 39, 40 On the other hand, the Cox-2 expression is closely linked to carcinogenesis and progression of colon cancers, 41, 42 benign colon polyps, and the majority of gastric cancers have been reported to show increased expression of Cox-2. 43, 44 Recently, the Cox-2 expression was shown for melanoma, whereas benign nevi and epithelium were reported to be Cox-2 negative. 45 We also showed previously the transcriptional activity of the Cox-2 promoter within adenovirual vectors in melanoma cell lines, but not in nonmalignant primary melanocytes.
14 Thus, the Cox-2 appeared a promising candidate for melanoma targeting.
CXCR4, has been mapped to chromosome 2 (2q21) and contains two exons of 103 and 1563 bp interrupted by a Figure 1 Gene expression in melanoma cell lines. Expressions of Cox-2, CXCR4, EGP-2, and survivin mRNA in melanoma cell lines as detected by real-time PCR as described in Materials and methods. The cell lines used in this study were Mel-624, A375M, SK-MEL-28, MeWo melanoma cell lines, and a human dermal epithelial melanocyte, HEM, as a normal control. mRNA levels were represented as copy number/ng total RNA. GAPDH mRNA was determined in parallel as an internal control.
Promoter activity in melanoma B Lu et al 2132 bp intron precisely between codons 5 and 6 of the coding sequences. 46 Recently, Mü ller et al 15 have demonstrated that CXCR4 expression is markedly upregulated in breast cancer cells, but undetectable in normal mammary epithelial cells. Robledo's group demonstrated that CXCR4 and CXCR3 are overexpressed in human melanoma cells. 47 Furthermore, recent evidences point to the SDF-1a-CXCR4 axis as playing a role in progression to metastasis in a number of tumor contexts, [48] [49] [50] including melanoma. 47, 48 In this study, we evaluate the second candidate TSP in the potential utilization as a TSP for melanoma gene therapy.
The survivin gene is a member of the IAP protein family, known to play an important role in the growth and progression of a variety of cancers. Recently, the survivin gene has been described as being selectively expressed in some of the most common human neoplasms, such as breast cancer, 51 pancreatic cancer, 52 esophageal carcinoma, 53 primary glioblastoma, 54 ovarian cancer, 55 and melanomas, 56, 57 but is undetectable in normal differentiated tissues. 20 Survivin expression is correlated with clinical progression, 58, 59 and resistance to chemo-and radiotherapy. 60 A possible mechanism of enhanced tumor survival with high levels of survivin has been suggested to involve modulation of the apoptosis pathway, 61, 62 and may depend on inhibition of the two early apoptotic enzymes caspase-3 and caspase-7, 63 thus preventing programmed cell death. This mechanism is supported by the observation that downregulation of survivin expression by induction of the effector cell protease receptor-1 (EPR-1) enhances apoptosis, reduces Comparison of the survivin promoter activity with the EGP-2 promoter activity in primary melanoma cells. Panel a: survivin and EGP-2 mRNA levels were determined by real-time PCR in two primary melanomas, P-1 and P-2, and a normal control, HEM. The mRNA levels are represented as copy number/ng total RNA. GAPDH mRNA was determined in parallel as an internal control. Panel b: two primary melanoma cells, P-1 and P-2, and one normal control, HEM, were infected with an MOI of 10 PFU/cell of reAdGL3BSurvivin, reAdGL3BEGP-2, or AdGL3BCMV. Luciferase activity was determined 48 h after infection. All luciferase values were normalized for ease of comparison, with control, reAdGL3BCMV.
Promoter activity in melanoma B Lu et al tumor growth potential, and results in an increased sensitivity to anticancer agents. 64 Thus, the survivin promoter was a rational candidate TSP for melanoma cancer therapies.
Finally, the EGP-2 is a 40 kDa cell adhesion molecule also known as Ep-CAM or the pancarcinomaassociated antigen 17-1A. 23 Recently, the evidences showed EGP-2 is expressed as a stable transmembrane protein at high levels on the surface of most carcinomas, including the breast, 65, 66 ovary, 67 colon, 68 and lung cancers. 69 However, expression of EGP-2 has not yet been reported in melanoma. 32 Our data revealed that EGP-2 is rarely expressed in melanomas, similar to previous studies.
All promoters tested in this study showed low induction of reporter luciferase gene in Ad contexts in most mouse organs. Compared to the CMV promoter, the promoter activities in the liver (in Table 2 ) were 0.32, 0.07, 0.024, and 0.067% for the Cox-2, CXCR4, EGP-2, and survivin promoter, respectively. This demonstrated that these four promoters are not generally weak, but almost negative in the liver, exhibiting a 'liver-off' profile. This is important for transcriptional targeting in gene therapy via the Ad vectors, because more than 90% of the reAd usually localize to the liver. Interestingly, the Cox-2 and EGP-2 promoter had a high expression in the intestine, 120 and 110% of CMV activities. This is the reason why these two promoters are widely used in colon cancers. The CXCR4 promoter had a high expression in kidney, 44% of luciferase level relative to the CMV promoter. We have previously confirmed overexpression of luciferase reporter gene driven by the CXCR4 promoter in a number of RCC (metastatic renal cell carcinoma), in contrast to normal host cells and several cancer cell lines of nonrenal origin (data not shown here and the manuscript submitted). In addition, the survivin promoter showed lower activity than the other three promoters in all of the organs examined by quantitative real-time PCR except in the intestine (28% of RLU of the CMV promoter). Although the survivin promoter exhibited a high activity in the intestine, the absolute value in the intestine (776 RLU/mg protein) was only less than 4% of that in the liver (29 826 RLU/mg protein). Our data correlated with previous data that the survivin protein was detectable in all of cancer cell lines examined but not in most adult differentiated mouse tissues. 21 The transcriptional targeting data were shown in Figure 2 (panels a-c) . With the exception of EGP-2, three promoters, the Cox-2, CXCR4, and survivin promoter, exhibited high activities in four melanoma cell lines. Clearly, survivin is a promising tumor-specific promoter for melanoma tumor cells due to the following reasons: (1) the survivin promoter has low background activity in major mouse organs compared to the other three promoters; (2) the survivin gene has a high endogenous expression verified by quantitative real-time PCR in four melanoma cell lines and low in HEM; (3) the survivin promoter in reAd exhibits high activities in four melanoma cell lines but low in HEM; (4) the Cox-2 promoter has similar level of the activity as the survivin promoter in four tested melanoma cell lines. However, the Cox-2 has huge variation (ie 14, 0.4, 2.1, and 0.8%) of luciferase activities induced by the CMV promoter in SK-MEL-28, A375M, MeWo, and Mel-624 cell lines, respectively; (5) the CXCR4 has similar activity as that induced by the survivin promoter in four melanoma cell lines, but the CXCR4 promoter has a high background (7.7% of CMV activity) in HEM, a host melanocytes, that is, higher than the average percent of RLU (6.8%) of four melanoma cell lines; (6) thus, only the survivin promoter perfectly exhibits 'tumor-on/liver-off' profile in melanoma cells, and shows both P-values less than 0.01 compared to the promoter activities of the survivin promoter with that of the EGP-2 promoter, or compared to the survivin promoter activities in melanoma cell lines with that in HEM, a normal control. We also used human fibroblasts and human mammary epithelial cells as normal controls; the survivin promoter activities in both controls were 1.7 and 0.1% of CMV activity, respectively (data not shown).
In our analysis using established cell lines, the activities of the survivin promoter in an Ad construct were much higher than that of EGP-2 promoter in multiple melanoma cell lines. However, a discrepancy between gene transfer efficiencies in cancer cell lines and clinical trails has been described to exist. 37 Therefore, to further test promoter function in a system that closely recapitulates the in vivo situation, experiments were performed to evaluate these promoters in primary tumor cells from patients. Again, the survivin promoter had high activities (5.1 and 11.3% of CMV activity), the EGP-2 promoter, however, had undetectable activities (o0.01%) in both primary melanoma cells, P-1 and P-2, respectively. Obviously, the mRNA levels of two genes correlated with transcriptional activities of their corresponding promoters in recombinant adenoviral context in two primary melanoma samples. The data revealed that gene expression efficiencies for reAdGL3BSurvivin vector are very similar between established melanoma cell lines and primary melanoma cells.
In conclusion, the activity of the survivin promoter is high in both established melanoma cell lines and primary melanoma cells, but low in HEMs, HEM, liver, and most normal major organs. This promoter is therefore a promising candidate for tumor-specific gene applications in melanoma treatment, and for viral oncolysis with CRAds, conditionally replicating adenoviruses.
